Tune Therapeutics welcomes noted industry leader Dr. John McHutchison as a member of its Board of Directors
A former Assembly Bio and Gilead executive brings decades of development experience novel therapeutics to Tune’s growing pipeline of genetic tuning therapies
DURHAM, N.C. & SEATTLE, January 17, 2023–(BUSINESS WIRE)–Tune Therapeutics, a biotechnology company pioneering the creation of genetic tuning (epigenomic editing) therapies, today announced the addition of John McHutchison AO, MD – former CEO at Assembly Biosciences, Inc., and CSO at Gilead Sciences, Inc. – to its board of directors. McHutchison joins the company as an industry leader, with extensive experience in the development of novel treatments to benefit patients suffering from serious, complex diseases.
Multimedia is featured in this press release. You can view the complete release here. https://www.businesswire.com/news/home/20230117005456/en/
John McHutchison, Photo: Business Wire
“Dr. McHutchison’s experience will be pivotal as we advance our novel genetic tuning candidate therapies,” said Matt Kane, CEO of Tune Therapeutics. “John’s background in a broad range of modalities and therapeutic areas – right across the R&D spectrum – is incredibly well aligned with our mission to unlock the power of the epigenome in the treatment of common, complex, and multigenic disease. John is a great partner and I look forward to working with him as we bring this modality to the clinic.
This move marks Dr. McHutchison’s first since retiring as President and CEO of Assembly Biosciences at the end of 2022. At Assembly, he led the company’s progress in the anti-viral space before transitioning to the board of directors and chairing the Science and Technology Committee. Before Assembly, he was Chief Scientific Officer and Head for Research and Development at Gilead Sciences. He led the development and implementation of a wide range of liver-directed therapies including antiviral regimens that treat HCV and nonalcoholic steatohepatitis (NASH) treatments. John was also instrumental in Gilead’s transformative acquisition of Kite Therapeutics, and its subsequent leadership position in the CAR T cell therapy field.
Dr. McHutchison said, “Now that precision tuning has become a reality for the epigenome, we are witnessing the critical moment in the future of medicine.” Tune Therapeutics’ powerful and flexible TEMPO platform is making huge strides in a variety of applications and diseases. The potential is immense. I expect great things to happen and am happy to support the company’s exciting and crucial work.”
Tune Therapeutics
Tune Therapeutics’ versatile and powerful TEMPO epigenomic controller platform is a pioneer in a new therapeutic modality. It can fine-tune any network of genes and unlock the potential of regenerative medicines. Tune Therapeutics has a wealth of experience and is passionate about exploration and innovation. Tune is at an important turning point in the history and evolution of genetic medicine. Tune can now address thousands of complex and common diseases without any curative treatment.
Businesswire.com – View the source version https://www.businesswire.com/news/home/20230117005456/en/
Contacts